Life Science Investing CORRECTION: Nuvectis Pharma, Inc. Reports Third Quarter 2025 Financial Results and Business Highlights
Life Science Investing Nuvectis Pharma, Inc. Reports Third Quarter 2025 Financial Results and Business Highlights
Life Science Investing Nuvectis Pharma Provides Poster Presentation Highlights for NXP900 from the 2025 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
Life Science Investing Nuvectis Pharma Announces Upcoming Presentations for NXP900 at the 2025 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
Life Science Investing Nuvectis Pharma Appoints Biotech Executive Juan Sanchez, MD, to the Board of Directors
Life Science Investing Nuvectis Pharma to Participate at the H.C. Wainwright 27th Annual Global Investment Conference
CORRECTION: Nextech3D.ai Provides Shareholder Update on Krafty Labs Acquisition and Announces $321,917 CEO Investment
Goldgroup Secures Ownership of the San Francisco Gold Mine Acquiring 100% of Molimentales del Noroeste, S.A. De C.V.
